Bioasis Technologies Inc. (BIOAF)
OTCMKTS · Delayed Price · Currency is USD
0.0000
-0.0002 (-99.50%)
At close: Nov 10, 2025
Bioasis Technologies Company Description
Bioasis Technologies Inc. operates as a biopharmaceutical company.
The company utilizes its proprietary xB3 platform to deliver therapeutics across the blood-brain barrier and treat central nervous system disorders in areas of high unmet medical need.
Bioasis Technologies Inc. is based in New Haven, Connecticut.
Bioasis Technologies Inc.
| Country | Canada |
| Founded | 2006 |
| Industry | Biotechnology |
| Sector | Healthcare |
| CEO | Deborah Rathjen |
Contact Details
Address: 157 Church Street New Haven, Connecticut 06510 United States | |
| Phone | 203 533 7082 |
| Website | bioasis.us |
Stock Details
| Ticker Symbol | BIOAF |
| Exchange | OTCMKTS |
| Fiscal Year | March - February |
| Reporting Currency | CAD |
| ISIN Number | CA09064N1033 |
| SIC Code | 2835 |
Key Executives
| Name | Position |
|---|---|
| Dr. Deborah Ann Rathjen B.Sc. (Hons.), FTSE, M.A.I.C.D., Ph.D., Q.C. | Chief Executive Officer and President |
| David P. Jenkins | Chief Financial Officer |
| Graeme Dick | Director of Investor Relations |
| Aaron Elton | Director of Marketing |
| Dr. Mei Mei Tian | Vice President and Head of External Research |